Martingale Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Martingale Asset Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$129K	Buy	+21,096	New	+$175K	﹤0.01%	787

Other funds holding DNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.18B AUM 27.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Martingale Asset Management's DNA Position: Q1 2026 in Review

Martingale Asset Management opened a new position in Ginkgo Bioworks (DNA) in Q1 2026: 21,096 shares worth $129K. The stake represents ﹤0.01% of the portfolio and ranks #787 among its holdings.

174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

Martingale Asset Management held 21,096 shares of Ginkgo Bioworks worth $129K as of Q1 2026.
Ginkgo Bioworks was a new Martingale Asset Management position in Q1 2026.
Ginkgo Bioworks made up ﹤0.01% of Martingale Asset Management's portfolio in Q1 2026, its #787 holding.
174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.